Also known as: acute lymphoblastic leukaemia, Acute Lymphoblastic Leukaemia
Acute lymphoblastic leukemia (ALL) is an aggressive blood and bone marrow cancer in which too many lymphocytes or lymphoblasts are produced. The disease progresses quickly without treatment and can involve both marrow and peripheral blood.
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
The FDA approved Tregzi (Orca-T), a first-of-its-kind regulatory T cell-based immunotherapy, for adults with blood cancers undergoing matched donor stem cell transplants. Approval was based on the PRECISION-T trial, in which 78% of treated patients achieved chronic GVHD-free survival at one year versus 38.4% with standard transplant.
The FDA has approved Tregzi, a donor-derived T-cell immunotherapy, to reduce the risk of chronic graft-versus-host disease following stem cell transplant in adults with high-risk blood cancers. In a pivotal trial, 78% of recipients were alive and free of severe chronic GVHD at one year versus 38.4% with standard transplant.
The FDA approved Orca-T (Tregzi) for matched donor hematopoietic stem cell transplantation in adults with hematologic malignancies. Phase 3 Precision-T data showed reduced graft-versus-host disease across leukemia and MDS populations, with experts calling it a 'big advance' requiring further comparison with post-transplant cyclophosphamide.
ASH has published new clinical practice guidelines for frontline and relapsed/refractory ALL management in adolescents and young adults, endorsing pediatric-inspired regimens, asparaginase therapy, and immunotherapy over traditional chemotherapy.
The American College of Sports Medicine has published the first evidence-based exercise guidelines for children and adolescents with cancer, recommending safe, supervised activity during treatment. A new clinical trial is also evaluating structured exercise for young sarcoma patients undergoing chemotherapy to improve outcomes and quality of life.
WHO in January 2024 launched its first list of priority childhood cancer drug formulations, naming six medicines that still lack optimal child-friendly versions. The agency says about 400,000 children and adolescents develop cancer each year and is working to expand access to safe, effective paediatric formulations.
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
Researchers have engineered immune cells to sense cancer metabolites, improving tumor infiltration in solid cancers. Separate studies identify Kappa and Lambda Myeloma Antigens as specific targets for multiple myeloma treatment, while mRNA-based personalized cancer vaccines show promise through AI-driven neoantigen selection.
New AI-powered platforms enable same-day cancer treatment decisions and streamline clinical trial matching. University of Utah's μPharma chip predicts drug responses in under four hours, while City of Hope's HopeLLM system matches patients to trials across its national network.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07770698 |
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07763054 |
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients |
RECRUITING | |
| NCT07751588 |
Plasma ctDNA Monitoring in Pediatric Acute Leukemia |
NOT_YET_RECRUITING | |
| NCT07710781 |
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies |
NOT_YET_RECRUITING | NA |
| NCT07684131 |
EWALL-PH OBSERVARTORY 2022 |
RECRUITING | |
| NCT07644351 |
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients |
COMPLETED | |
| NCT07634653 |
Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL) |
RECRUITING | NA |
| NCT07623655 |
CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia |
NOT_YET_RECRUITING | |
| NCT07616089 |
Phase I Study of FXS0683 in the Treatment of Blood Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07584889 |
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies |
RECRUITING | PHASE1/PHASE2 |
